Overview
- Viz.ai is partnering with Cortechs.ai to integrate the NeuroQuant and NeuroQuant MS platforms into its care coordination platform.
- The collaboration initially focuses on multiple sclerosis and expands Viz.ai’s neuro offerings into neurodegenerative disease.
- The partnership aims to help clinicians identify, characterize, and coordinate care for MS patients at scale.
The News
Viz.ai announced a collaboration with Cortechs.ai to integrate NeuroQuant and NeuroQuant MS quantitative neuroimaging tools into the Viz.ai platform. The partnership will initially focus on multiple sclerosis, bringing quantitative MRI analysis directly into Viz.ai’s care coordination workflow.
The integration combines Cortechs.ai’s neuroimaging and quantitative analysis capabilities with Viz.ai’s AI-powered care coordination infrastructure, giving clinicians access to both quantitative imaging insights and tools to connect patients with the appropriate care teams. With a footprint of nearly 2,000 U.S. hospitals, Viz.ai aims to expand access to quantitative neuroimaging and accelerate the identification and management of patients with neurodegenerative diseases.
Industry Perspective
AI-powered neuroimaging is increasingly helping clinicians extract more detailed and standardized insights from complex imaging data. Combining quantitative analysis with care coordination may help health systems move beyond isolated diagnostic tools toward more connected pathways for identifying and managing chronic neurological conditions.
Strategic Impact
The partnership expands Viz.ai’s presence in neurodegenerative disease and strengthens its Neuro Suite beyond existing neurovascular applications. By combining quantitative MRI analysis with large-scale care coordination, the companies aim to support earlier patient identification, improve clinical decision-making, and build a more connected approach to MS care.
Source: Businesswire
